Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

In a phase 2 trial, bepirovirsen, an antisense oligonucleotide that targets all hepatitis B virus mRNAs, resulted in sustained loss of hepatitis B surface antigen and HBV DNA in 9 to 10% of participants with chronic HBV infection.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-11, Vol.387 (21), p.1957-1968
Hauptverfasser:	Yuen, Man-Fung, Lim, Seng-Gee, Plesniak, Robert, Tsuji, Keiji, Janssen, Harry L.A., Pojoga, Cristina, Gadano, Adrian, Popescu, Corneliu P., Stepanova, Tatyana, Asselah, Tarik, Diaconescu, Gheorghe, Yim, Hyung Joon, Heo, Jeong, Janczewska, Ewa, Wong, Alexander, Idriz, Nevin, Imamura, Michio, Rizzardini, Giuliano, Takaguchi, Koichi, Andreone, Pietro, Arbune, Manuela, Hou, Jinlin, Park, Sung Jae, Vata, Andrei, Cremer, Jennifer, Elston, Robert, Lukić, Tamara, Quinn, Geoff, Maynard, Lauren, Kendrick, Stuart, Plein, Helene, Campbell, Fiona, Paff, Melanie, Theodore, Dickens
Format:	Artikel
Sprache:	eng
Schlagworte:	Alanine transaminase Antigens Antisense oligonucleotides Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Antiviral drugs Chronic infection DNA, Viral - blood Fever Gastroenterology Gastroenterology General Genetics Hepatitis Hepatitis B Hepatitis B e Antigens - blood Hepatitis B surface antigen Hepatitis B Surface Antigens - blood Hepatitis B virus - genetics Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology Humans Hypothesis testing Infections Infectious Disease Injections, Subcutaneous International organizations Laboratories Liver cancer Liver Disease Liver diseases Nucleoside analogs Nucleotide analogs Oligonucleotides, Antisense - administration & dosage Oligonucleotides, Antisense - adverse effects Oligonucleotides, Antisense - therapeutic use Placebos Response rates RNA Therapeutics RNA, Messenger - drug effects RNA, Viral - drug effects Treatment Outcome Viral Infections
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a phase 2 trial, bepirovirsen, an antisense oligonucleotide that targets all hepatitis B virus mRNAs, resulted in sustained loss of hepatitis B surface antigen and HBV DNA in 9 to 10% of participants with chronic HBV infection.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2210027